Phase II Study of Gleevec/Imatinib Mesylate (STI-571 NSC 716051) in Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas
Study on Investigational Treatment for Asthma
Not Recruiting
3 years - 65 years
All
Phase
N/A
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Plexiform Neurofibromas
Age:
3 years - 65 years
Gender: All
Who can participate: Individuals aged 18 to 65 years with a diagnosis of asthma may be eligible. Participants should not have other chronic respiratory conditions.
Study details: Participants will be randomly assigned to receive either the investigational treatment or a placebo. They will need to attend regular appointments for assessments and follow-up.
Updated on
19 Feb 2024.
Study ID: 0512-25
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
